In vivo studies on the potential anticancer platinum(II) complexes containing selenones and Dithiocarbamates

Platinum-based metallodrugs are the major source of chemotherapy for the treatment of different types of cancers, but their successes have been hampered by severe side effects such as nephrotoxicity, lost vision, drug resistance, etc. The recent advancement in the invention of a novel platinum(II) compounds with square planar structure is leading to the innovation in the field of chemotherapy drug formulation. New derivatives of platinum(II) containing the selenone and dithiocarbamate ligands having the general formula, cis-[Pt(NH3)2(Selenone)2](NO3)2 and [Pt(cyclopentdienyl)(DTC)](PF6)2 have been synthesized and characterized using elemental analysis, IR, and NMR (1H, 13C, 77Se) spectroscopy. The spectroscopic data indicated the coordination of selenones and dithiocarbamates to platinum(II). The in vitro cytotoxicity of these complexes as well as of cisplatin was investigated using MTT assay against cancer cell lines of HeLa (cervical cancer cells), A549 (Lung cancer cells) and HCT-116 (colon cancer cells). The IC50 values showed promising cytotoxicity for the prepared platinum(II) complexes, which are better with respect to cisplatin. In the present study, we proposed to examine the in vivo studies of these potential anticancer platinum(II) complexes (1-4) on mice. The findings of the study will enhance the knowledge and understanding of these complexes along with their effect in mice. Also, will help in the development of a new generation of anticancer drugs with fewer side effects than others drugs currently available in the market.